What's breaking now, across thousands of outlets.
DefenCath revenue hit $66.1M as CorMedix expands dialysis partnerships and advances REZZAYO.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
ALLY system placements accelerate as recurring revenue hits 83% of total sales.
Phase 3 trial underway for iopofosine I 131 in Waldenstrom's macroglobulinemia.
Defense demand fuels record consumables revenue amid MarkForged acquisition push.
DropSite News exposes how the too-cutely-named Israel front Honest Reporting managed to secure funds from the Knight Foundation
Market participants are warning that a lack of predictability when it comes to the US Treasury’s debt management strategy could ultimately portend higher borrowing costs.
Online stockbroking platform Upstox has reportedly begun preliminary discussions with investment banks for a potential IPO. The Mumbai-based brokerage is…
